Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC
Accepted 2022-05-31 00:00:00 ET · period of report 2022-04-29 · accession 0001567619-22-011966 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-31 | 2022-04-29 | BMRN | Ajer Jeffrey Robert | EVP, Chief Commercial Off | A - Grant | $62.41 | +340 | 55.4K | +0.6% | +$21.2K | |
| 2022-05-31 | 2022-05-26 | BMRN | Ajer Jeffrey Robert | EVP, Chief Commercial Off | S - Sale | $78.94 | -1,308 | 54.1K | -2% | -$103.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-29 | A | A | 340 | $62.41 | 55,417 | D | — | — | (F1) Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2022-05-26 | S | D | 1,308 | $78.94 | 54,109 | D | — | — | (F2) Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. |